SPY311.36-0.82 -0.26%
DIA263.33+0.16 0.06%
IXIC9,615.81-67.10 -0.69%
News
GBT
--
0.00%
--
GBT Announces New Employment Inducement Grants
GlobeNewswire · 1d ago
Edited Transcript of GBT earnings conference call or presentation 6-May-20 8:30pm GMT
Thomson Reuters StreetEvents · 2d ago
GBT Announces Participation at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast
GlobeNewswire · 2d ago
Is Global Blood Therapeutics a Buy?
Motley Fool · 6d ago
3 Top Pharma Stocks to Buy Right Now
Healthcare investors can look past the development risk. Global Blood Therapeutics (NASDAQ: GBT) crushed analyst estimates when it reported its first-quarter results on May 6. In its first full quarter on the market, Global Blood's sickle cell disease drug O
Motley Fool · 05/24 16:25
How Global Blood Therapeutics (GBT) Stock Stands Out in a Strong Industry
Zacks · 05/15 15:58
Global Blood Therapeutics Highlights Data Presentations At Upcoming European Hematology Association Congress Jun. 12
Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that four abstracts will be presented during the virtual edition of the 25th Annual European Hematology Association (EHA) Congress taking place June
Benzinga · 05/14 13:26
GBT Announces Upcoming Data Presentations During Virtual Edition of 25th Annual European Hematology Association Congress
The abstracts include a retrospective analysis of data from the landmark STOP 2 study linking higher hemoglobin levels to lower transcranial Doppler (TCD) flow velocity, a predictor of stroke risk in children with sickle cell disease (SCD), and three encore pr
GlobeNewswire · 05/14 13:05
Global Blood Therapeutics, Inc. 2020 Q1 - Results - Earnings Call Presentation
Seeking Alpha - Article · 05/07 18:13
Oppenheimer Maintains Outperform on Global Blood Therapeutics, Raises Price Target to $101
Oppenheimer maintains Global Blood Therapeutics (NASDAQ:GBT) with a Outperform and raises the price target from $88 to $101.
Benzinga · 05/07 14:22
Wells Fargo Maintains Overweight on Global Blood Therapeutics, Raises Price Target to $133
Wells Fargo maintains Global Blood Therapeutics (NASDAQ:GBT) with a Overweight and raises the price target from $122 to $133.
Benzinga · 05/07 13:50
GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., May 07, 2020 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on May 1, 2020, the compensation committee of GBT’s board.
GlobeNewswire · 05/07 12:00
Morgan Stanley Maintains Equal-Weight on Global Blood Therapeutics, Raises Price Target to $75
Morgan Stanley maintains Global Blood Therapeutics (NASDAQ:GBT) with a Equal-Weight and raises the price target from $70 to $75.
Benzinga · 05/07 11:59
Global Blood Therapeutics Reports Q1 Beat, Impressive Oxbryta Sales
SmarterAnalyst · 05/07 10:48
Global Blood Therapeutics, Inc. (GBT) CEO Ted Love on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/07 03:26
Global Blood Therapeutics EPS beats by $0.31, beats on revenue
Global Blood Therapeutics (NASDAQ:GBT): Q1 GAAP EPS of -$1.20 beats by $0.31. Revenue of $14.12M beats by $10.47M. Press Release
seekingalpha · 05/07 01:07
Global Blood Therapeutics (GBT) Reports Q1 Loss, Tops Revenue Estimates
Global Blood (GBT) delivered earnings and revenue surprises of 18.37% and 268.91%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/06 21:35
GBT Reports Recent Business Progress and First Quarter 2020 Financial Results
GlobeNewswire · 05/06 21:05
Global Blood Therapeutics Q1 EPS $(1.200) Beats $(1.510) Estimate, Sales $14.118M Beat $3.490M Estimate
Global Blood Therapeutics (NASDAQ:GBT) reported quarterly losses of $(1.200) per share which beat the analyst consensus estimate of $(1.510) by 20.53 percent. This is a 37.93 percent decrease over losses of $(0.870) per
Benzinga · 05/06 20:36
The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week Highs May 5)
Benzinga · 05/06 14:36